Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients

NCT ID: NCT06140147

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1850 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-27

Study Completion Date

2028-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to assess the beneficial and harmful effects of a restrictive strategy for administration of non-resuscitation fluids in adult patients with septic shock.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
The clinical team caring for participants will not be blinded due to the nature of the intervention. The participants and their family will not be actively informed about group allocation. The steering group, author group, trial statistician, outcome assessors, prognosticators, the trial coordinating team, manuscript writers and the data safety and monitoring committee will be blinded to group allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protocolised reduction of non-resuscitation fluids

Participants receive non-resuscitation fluids according to a pre-defined protocol starting within two hours of randomization. The intervention is continued for the duration of the ICU admission up to a maximum of 90 days.

Group Type EXPERIMENTAL

Protocolised reduction of non-resuscitation fluids

Intervention Type OTHER

Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)

Usual Care

Participants receive non-resuscitation fluids according to local routines.

Group Type OTHER

Usual care

Intervention Type OTHER

Participants receive non-resuscitation fluids according to local routines, with the following stipulations:

Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.

Medications: concentrated per local protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Protocolised reduction of non-resuscitation fluids

Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)

Intervention Type OTHER

Usual care

Participants receive non-resuscitation fluids according to local routines, with the following stipulations:

Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.

Medications: concentrated per local protocol

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (≥ 18 years of age)
* Septic shock according to the Sepsis 3 criteria at any time within 12 hours after ICU admission (suspected or confirmed infection, plasma lactate above 2 mmol/L, and infusion of vasopressor/inotrope to maintain mean arterial pressure of 65mmHg or above after receiving adequate fluid resuscitation \[\> 1L within 12 h of screening\]) and need for vasopressors at the time of screening.

Exclusion Criteria

* Confirmed or suspected pregnancy
* Previous inclusion in the trial
* Screened more than 12 hours after ICU admission
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Skane

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Bentzer

Role: PRINCIPAL_INVESTIGATOR

Region Skåne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helsinki University Hospital

Helsinki, , Finland

Site Status NOT_YET_RECRUITING

Tampere University Hospital

Tampere, , Finland

Site Status NOT_YET_RECRUITING

Danderyd Hospital

Danderyd, , Sweden

Site Status RECRUITING

Malar Hospital

Eskilstuna, , Sweden

Site Status NOT_YET_RECRUITING

Falun Hospital

Falun, , Sweden

Site Status RECRUITING

Sahlgrenska University Hospital

Gothenburg, , Sweden

Site Status RECRUITING

Östra Hospital

Gothenburg, , Sweden

Site Status NOT_YET_RECRUITING

Halmstad Hospital

Halmstad, , Sweden

Site Status RECRUITING

Helsingborg Hospital

Helsingborg, , Sweden

Site Status RECRUITING

Skåne University Hospital, Lund

Lund, , Sweden

Site Status RECRUITING

Skåne University Hospital, Malmö

Malmo, , Sweden

Site Status RECRUITING

Norrtälje Hospital

Norrtälje, , Sweden

Site Status RECRUITING

Örebro University Hospital

Örebro, , Sweden

Site Status RECRUITING

Östersund Hospital

Östersund, , Sweden

Site Status RECRUITING

Södertälje Hospital

Södertälje, , Sweden

Site Status NOT_YET_RECRUITING

Stockholm South General Hospital (SÖS)

Stockholm, , Sweden

Site Status RECRUITING

University Hospital of Umeå

Umeå, , Sweden

Site Status RECRUITING

Uppsala University Hospital

Uppsala, , Sweden

Site Status RECRUITING

Varberg Hospital

Varberg, , Sweden

Site Status RECRUITING

University Hospital of Wales

Cardiff, , United Kingdom

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland Sweden United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peter Bentzer

Role: CONTACT

+46 42-4061111

Jane Fisher

Role: CONTACT

References

Explore related publications, articles, or registry entries linked to this study.

Bentzer P, Linden A, Olsen MH, Lilja G, Fisher J, Sjovall F, Kander T, Lengquist M, Samuelsson L, Unden J, Palmnas E, Oras J, Cronhjort M, Balintescu A, Lind A, Ahlstrom B, Meirik M, Savilampi J, Pekkarinen P, Berggren A, Oscarsson N, Said M, Castegren M, Faria S, Hemberg L, Linder A, Lipcsey M, Skrifvars MB, Wise MP, Nielsen N, Jakobsen JC. Protocolized REDUction of Non-Resuscitation Fluids in SEptic Shock Patients. A Protocol for the REDUSE Randomized Clinical Trial. Acta Anaesthesiol Scand. 2025 Aug;69(7):e70095. doi: 10.1111/aas.70095.

Reference Type DERIVED
PMID: 40671283 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REDUSE

Identifier Type: -

Identifier Source: org_study_id